Portal de investigação
Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial
Data de publicação:
Autores da FMUP
Participantes de fora da FMUP
- Verdonschot, JAJ
- Pellicori, P
- Brunner-La Rocca, HP
- Clark, AL
- Cosmi, F
- Cuthbert, J
- Girerd, N
- Mariottoni, B
- Petutschnigg, J
- Rossignol, P
- Cleland, JGF
- Zannad, F
- Heymans, SRB
- HOMAGE Heart Omics AGEing Consorti
Unidades de investigação
Abstract
Background Patients with diabetes mellitus (DM) are at increased risk of developing heart failure (HF). The "Heart OMics in AGEing" (HOMAGE) trial suggested that spironolactone had beneficial effect on fibrosis and cardiac remodelling in an at risk population, potentially slowing the progression towards HF. We compared the proteomic profile of patients with and without diabetes among patients at risk for HF in the HOMAGE trial. Methods Protein biomarkers (n = 276) from the Olink (R) Proseek-Multiplex cardiovascular and inflammation panels were measured in plasma collected at baseline and 9 months (or last visit) from HOMAGE trial participants including 217 patients with, and 310 without, diabetes. Results Twenty-one biomarkers were increased and five decreased in patients with diabetes compared to non-diabetics at baseline. The markers clustered mainly within inflammatory and proteolytic pathways, with granulin as the key-hub, as revealed by knowledge-induced network and subsequent gene enrichment analysis. Treatment with spironolactone in diabetic patients did not lead to large changes in biomarkers. The effects of spironolactone on NTproBNP, fibrosis biomarkers and echocardiographic measures of diastolic function were similar in patients with and without diabetes (all interaction analyses p > 0.05). Conclusions Amongst patients at risk for HF, those with diabetes have higher plasma concentrations of proteins involved in inflammation and proteolysis. Diabetes does not influence the effects of spironolactone on the proteomic profile, and spironolactone produced anti-fibrotic, anti-remodelling, blood pressure and natriuretic peptide lowering effects regardless of diabetes status. Trial registration NCT02556450.
Dados da publicação
- ISSN/ISSNe:
- 1475-2840, 1475-2840
- Tipo:
- Article
- Páginas:
- -
- Link para outro recurso:
- www.scopus.com
Cardiovascular Diabetology BioMed Central Ltd.
Citações Recebidas na Web of Science: 9
Citações Recebidas na Scopus: 10
Documentos
- Não há documentos
Filiações
Keywords
- Diabetes; Biomarker; Heart failure; Spironolactone; Fibrosis
Financiamento
Proyectos asociados
Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022
Citar a publicação
Verdonschot J,Ferreira JP,Pellicori P,Brunner HP,Clark AL,Cosmi F,Cuthbert J,Girerd N,Mariottoni B,Petutschnigg J,Rossignol P,Cleland JGF,Zannad F,Heymans SRB,HOMAGE Heart Omics AGEing C. Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial. Cardiovasc. Diabetol. 2021. 20. (1):163. IF:8,949. (1).
